The ability to specifically upregulate genes in vivo holds great therapeutic promise. Here we show that inhibition or degradation of natural antisense transcripts (NATs) by single-stranded oligonucleotides or siRNAs can transiently and reversibly upregulate locus-specific gene expression. Brain-derived neurotrophic factor (BDNF) is normally repressed by a conserved noncoding antisense RNA transcript, BDNF-AS. Inhibition of this transcript upregulates BDNF mRNA by two-to sevenfold, alters chromatin marks at the BDNF locus, leads to increased protein levels and induces neuronal outgrowth and differentiation both in vitro and in vivo. We also show that inhibition of NATs leads to increases in glial-derived neurotrophic factor (GDNF) and ephrin receptor B2 (EPHB2) mRNA. Our data suggest that pharmacological approaches targeting NATs can confer locus-specific gene upregulation effects.
A r t i c l e s
The number of noncoding RNAs in eukaryotic genomes increases as a function of developmental complexity 1, 2 . In addition, there is a great deal of diversity of noncoding RNAs expressed in the nervous system 3, 4 . Over the past few years, we and others have reported on functional natural antisense transcripts (NATs) and showed their potential involvement in human disorders, including Alzheimer's disease 5 , Parkinson's disease 6 and Fragile X syndrome 7 . NATs typically originate opposite the sense strand of many protein-coding genes, often overlapping in part with mRNA, promoter and regulatory regions 8, 9 . Multiple reports indicate that antisense transcripts are functional elements and use diverse transcriptional and posttranscriptional mechanisms to regulate gene expression (reviewed ref. 9 ). Previously, we showed that upregulation of CD97 coding mRNA can be attained by knockdown of its antisense RNA transcript 8 . Other reports indicated that siRNAs targeting promoter-derived noncoding RNAs caused upregulation of the progesterone receptor and other endogenous transcripts 10, 11 . Transcriptional activation of p21 (ref. 12) and the Oct4 promoter 13 were reported following NATs depletion. The existence of a human NAT that is transcribed opposite the gene encoding BDNF 14 , a member of the 'neurotrophin' family of growth factors, has been reported 15 . Here we functionally characterize this antisense transcript in more detail.
Neurotrophins, such as BDNF, belong to a class of secreted growth factors that are essential for neuronal growth, maturation 16, 17 , differentiation and maintenance 18 . BDNF is also essential for neuronal plasticity [19] [20] [21] and has been shown to be involved in learning and memory processes 22 . BDNF is suggested to synchronize neuronal and glial maturation 23 , participate in axonal and dendritic differentiation 24 and protect and enhance neuronal cell survival 25, 26 . Neurotrophin expression levels are impaired in neurodegenerative [27] [28] [29] [30] and in psychiatric and neurodevelopmental disorders [31] [32] [33] . The upregulation of neurotrophins is believed to have beneficial effects on several neurological disorders.
Here we characterize the role of BDNF antisense RNA (BDNF-AS, also annotated as BDNF-OS; nucleotide sequence of human BDNF-AS is provided in Supplementary Data 1) , which we demonstrate regulates the expression of sense BDNF mRNA and protein, both in vitro and in vivo. We also show that glial-derived neurotrophic factor (GDNF) and ephrin receptor B2 (EPHB2) can be upregulated by blocking endogenous NATs. Our strategy for upregulation of mRNA expression uses antisense RNA transcript inhibitory molecules, which we term antagoNATs. We show that endogenous gene expression can be upregulated in a locus-specific manner by the removal or inhibition of NATs, which are transcribed from most transcriptional units 8, 34 . Our study provides examples of functional noncoding RNAs that regulate protein output by altering chromatin structure, and we posit that this phenomenon is applicable to many other genomic loci.
RESULTS

Genomic organization of the human BDNF locus
Both BDNF mRNA and BDNF-AS display a complex splicing pattern; however, all variants share a common sense-antisense overlapping region 14, 35 . The transcription start site of human BDNF-AS is located on the positive strand of chromosome 11 ~200 kb downstream from the BDNF mRNA promoter. Transcription from this site gives rise to 16-25 splice variants each containing six to eight exons 14 . Common to all these variants is exon 4, which does not overlap with BDNF mRNA, and exon 5, which contains 225 nucleotides of full complementarity to all 11 splice variants of BDNF mRNA (Fig. 1a) . We searched our existing next-generation RNA sequencing data, which were inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation A r t i c l e s generated from brain RNA samples on the Illumina platform, for the presence of BDNF-AS transcript (unpublished data). RNA deep sequencing data confirmed expression of BDNF-AS transcript in human brain RNA samples ( Fig. 1b) . Therefore, BDNF-AS has the potential to form an in vivo RNA-RNA duplex with BDNF mRNA through overlap of 225 complementary nucleotides.
Identification of mouse Bdnf-AS transcript
Although several human EST's have been reported to have the potential of forming sense-antisense pairs with BDNF transcripts 14, 15 , the mouse antisense Bdnf transcript has not previously been identified and thus BDNF-AS has erroneously been reported as a primate-specific transcript by others 35 . Using 5′ and 3′ rapid amplification of cDNA ends (RACE), we identified two mouse Bdnf-AS transcripts (Fig. 1c) . Based on RACE data, we designed primers and probes for detection of mouse Bdnf-AS by real-time PCR (rtPCR). The combination of RACE experiments, followed by sequencing along with rtPCR, indicated the existence of a conserved noncoding antisense transcript to the mouse Bdnf mRNA. The mouse Bdnf-AS transcript has two splice variants containing 1 or 2 exons but both contain 934 nucleotides complementary to Bdnf mRNA (Fig. 1c) . The nucleotide sequence of mouse Bdnf-AS is provided in Supplementary Data 2. Although the architectures of BDNF-AS in human and mouse are not entirely similar, the 225-bp overlapping region is almost identical between these two species (90% homology across the two species).
Expression analysis of BDNF and BDNF-AS
We measured the relative levels of BDNF and BDNF-AS transcripts in various human, monkey and mouse tissues by rtPCR and RNA fluorescence in situ hybridization (FISH). We also measured the absolute levels of BDNF and BDNF-AS transcripts by generating standard curves using DNA vectors containing cDNA of each transcript ( Supplementary Fig. 1 ). In humans, BDNF mRNA levels are generally 10-to 100-fold higher than BDNF-AS transcript, except in the testis, kidney and heart, which contain equal or higher levels of BDNF-AS. Both transcripts are expressed in the brain, muscle and embryonic tissues ( Supplementary Fig. 2 ). BDNF mRNA levels were relatively low in all post-natal tissues examined except in brain, bladder, heart and skeletal muscle ( Supplementary Fig. 3 ). In rhesus monkeys (Supplementary Fig. 4 ) and mice (Supplementary Figs. 5 and 6), both transcripts are co-expressed in many tissues, which suggests BDNF-AS potential for regulation of BDNF mRNA.
Knockdown of BDNF-AS increases BDNF in vitro
To investigate the effect of antisense transcript degradation on sense expression levels, we designed three independent short interfering RNA (siRNA) molecules that targeted the nonoverlapping regions of the BDNF-AS transcript ( Fig. 1b and Supplementary Table 1 ). Transfection of these siRNAs into several human and mouse cell lines, including HEK293T cells, resulted in >85% knockdown of the BDNF-AS transcript, accompanied by a two-to fivefold upregulation of the BDNF transcript ( Fig. 2a) . The upregulation of BDNF mRNA was not related to the choice of endogenous controls (Supplementary Fig. 7 ). Mouse Bdnf-AS transcript is shorter than that of human and contains 1 or 2 exons. rtPCR primers, probes and siRNAs are designed to target the nonoverlapping parts of both transcripts. Blue asterisks and numbers below each denote target sites of siRNAs used in this study, as well as mBdnf-antagoNAT3(*3) and mBdnf-antagoNAT9 (*9).
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A r t i c l e s Control reactions that did not include reverse transcriptase or template did not yield any product, suggesting that our rtPCR reactions reliably detected the transcript and was not contaminated by genomic DNA. Additionally, we tested the final PCR products for each set of primers and probe on a gel to ensure that only one product was amplified ( Supplementary Fig. 8 ).
To monitor the sequential events after administration of BDNF-AStargeted siRNA, we treated HEK293T cells with BDNF-AS-targeting siRNA, and measured the endogenous expression of both BDNF mRNA and BDNF-AS transcripts at several time points ( Fig. 2b) . We observed downregulation of BDNF-AS at 6 h with maximum efficacy between 24 and 48 h and lasting up to 72 h ( Fig. 2b) . Upregulation of BDNF mRNA started 18 h after transfection and reached the maximum at 48 h then decreased at 72 h before returning to pretreatment levels by 96 h. These data show that a transient knockdown of NAT levels leads to a fully reversible increase in BDNF mRNA levels.
Moreover, we examined BDNF protein levels by enzyme-linked immunosorbent analysis (ELISA) after treating HEK293T cells with two active BDNF-AS siRNAs, control siRNA or scrambled siRNAs ( Fig. 2c) . We also measured BDNF protein level by western blot analysis following transfection of cells with BDNF-AS siRNA-1 or control siRNA ( Fig. 2d ). Both ELISA ( Fig. 2c ) and western blot analysis ( Fig. 2d ) experiments demonstrated that treatment of cells with siRNA targeting BDNF-AS considerably increased the expression of BDNF protein. We observed that the magnitude of BDNF protein upregulation (about twofold) was less than the extent of mRNA upregulation (two-to sevenfold). This suggests that protein upregulation is stoichiometrically discordant with mRNA in these cells, especially considering that one molecule of mRNA often produces more than one molecule of protein. Post-transcriptional regulatory mechanisms, such as microRNAs, may account for this potential discrepancy in BDNF protein output [36] [37] [38] (Supplementary Fig. 9 ).
BDNF-AS did not alter BDNF sense-RNA stability
To examine the effects of BDNF-AS transcripts on the stability of BDNF sense transcripts, we depleted BDNF-AS with siRNA and then treated cells with α-amanitin, an inhibitor of RNA polymerase II. We found that the baseline half-life for BDNF-AS was 15.3 h, nearly 3 h longer than that of the BDNF sense transcript ( Supplementary  Fig. 10 ). There was no detectable change in BDNF sense-RNA stability after reduction of BDNF-AS transcript, suggesting that unlike highly abundant antisense transcripts 5 , BDNF-AS does not alter BDNF sense-mRNA stability. Recently it has been suggested that some NATs can produce endogenous siRNAs from the overlapping region between sense and antisense RNAs. However, none of the endogenous siRNAs previously identified 39 in mouse oocytes originated from the Bdnf locus.
Targeting of BDNF-AS by antagoNATs
Having established that antisense transcripts play a key role in regulating the expression levels of sense transcripts, we sought to test an alternate, simpler way to relieve the inhibitory effects of NATs. We introduce the term antagoNAT here to describe a single-stranded modified DNA or RNA oligonucleotide that inhibits the activity of antisense transcript. We hypothesized that the use of antagoNATs should have a similar outcome on BDNF expression as observed with BDNF-AS siRNA. To test this hypothesis, we designed a set of oligonucleotides tiling the entire region of overlap between human BDNF-AS and BDNF. For these experiments, each antagoNAT was a 14-nucleotide oligonucleotide containing a mixture of 2′-O-methyl RNA and locked nucleic acid (LNA) modifications (Online Methods). We found several efficacious antagoNATs capable of upregulating BDNF mRNA. hBDNF-antagoNAT1 and hBDNF-antagoNAT4, which both target the first part of the overlapping region, produced the largest response ( Supplementary Fig. 11 ). Our data suggest that blockage of BDNF antisense RNA, by single-stranded antagoNATs, is sufficient in causing an increase in BDNF mRNA.
To see if this method was applicable in different species, we designed single-stranded, 16-nucleotide gapmers 40 consisting of three LNA-modified DNA bases at each of the ends with ten unmodified DNA bases in the middle, allowing for RNaseH cleavage. A r t i c l e s consistently showed a statistically significant (P < 0.001, twoway ANOVA) increase in Bdnf mRNA levels in mouse N2a cells ( Supplementary Fig. 12 ). To establish an optimal dosage for further in vitro studies, we performed concentration-response experiments with 11 different concentrations (1:3 serial dilutions ranging from 300 nM to 5 pM) of mBdnf-antagoNAT9, measuring fold changes in Bdnf mRNA levels ( Fig. 2e) . Bdnf mRNA levels increased with increasing concentrations of mBdnf-antagoNAT9 from 1-300 nM resulting in an EC 50 of 6.6 nM.
Knockdown of GDNF-AS increases GDNF mRNA in vitro
To examine whether antagoNATs could be used to upregulate other genes, we designed several antagoNATs targeting the GDNF antisense transcript, a low-abundance noncoding antisense RNA that overlaps with the sense transcript. We found two antagoNATs that increased the GDNF mRNA by three-to fourfold (Fig. 2f) . To help determine whether the effects were specific to nerve growth factor genes, or were perhaps applicable to a larger number of genes, we also used antagoNATs to target antisense transcripts of the ephrin type-B receptor 2 (EPHB2) gene, resulting in upregulation of EPHB2 mRNA in HEK293T cells (Supplementary Fig. 13 ).
Bdnf upregulation increases neuronal outgrowth
It is well established that BDNF stimulates neuronal outgrowth and adult neurogenesis 41, 42 . Therefore, to demonstrate that our strategy for upregulating gene expression can lead to functional consequences, we treated neurospheres with siRNA against Bdnf-AS then determined the effects on neurite outgrowth. We found that an increase in endogenous Bdnf due to the knockdown of Bdnf-AS transcript resulted in increased neurite outgrowth and maturation ( Fig. 3a-d) . These data suggest that the upregulation of endogenous Bdnf, due to inhibition of antisense RNA, induces neuronal differentiation in neuronal progenitor cells.
Knockdown of Bdnf-AS increases Bdnf in vivo
We used osmotic mini-pumps for intracerebroventricular delivery of mBdnf-antagoNAT9 to C57BL/6 mice. We selected mBdnf-antagoNAT9, which targets a nonoverlapping region of mouse Bdnf-AS, over other active antagoNATs because it increases Bdnf mRNA in vitro efficaciously. After 28 d of continuous antagoNAT infusion, Bdnf mRNA levels were increased across forebrain regions adjacent to the third ventricle in mice treated with mBdnf-antagoNAT9 as compared to a control oligonucleotide (Fig. 4a,b) . Bdnf mRNA and Bdnf-AS transcripts were unaltered in the hypothalamus, a structure that is not immediately adjacent to the third ventricle ( Fig. 4c) . Moreover, we find that antagoNAT-mediated blockade of Bdnf-AS results in increased Bdnf protein levels ( Fig. 4d,e) . These findings correspond with the in vitro data described above and indicate that the blockade of Bdnf-AS results in the increase of Bdnf mRNA and protein expression in vivo.
We injected BrdU in the mice treated with mBdnf-antagoNAT9 in the first week of the study for 5 d. After 28 d of continuous antagoNAT infusion, we performed histological examination of brain tissues and quantified neuronal proliferation and survival using Ki67 and BrdU markers, respectively. In mice treated with mBdnf-antagoNAT9, we observed an increase in cells expressing Ki67 (a marker of cell proliferation) as compared with control mice (Fig. 5a,b) . We quantified the number of Ki67-positive cells and found an increase in mice treated with mBdnf-antagoNAT9 compared with control oligonucleotide (Fig. 5c) . In mice treated with mBdnf-antagoNAT9, there was a significant increase in BrdU incorporation (surviving cells) as compared with the control oligonucleotide-treated npg mice (Fig. 5d ). There were no differences in hippocampal volume between control and mBdnf-antagoNAT9 treated mice (Fig. 5e) .
These findings demonstrate that Bdnf-AS regulates Bdnf levels in vivo.
Locus-specific effects of BDNF-AS degradation
To validate the specificity of the BDNF-AS targeting siRNA and to show locus-specific effects of antisense reduction, we performed rtPCR and found that the knockdown of BDNF-AS transcript increases BDNF mRNA without any effects on neurotrophic tyrosine kinase receptor type 2 (TrkB), a receptor for BDNF, or on neighboring genes (LIN7C and KIF18A) in both directions (Supplementary Fig. 14) .
BDNF-AS induces repressive chromatin marks
We hypothesized that BDNF-AS regulates BNDF mRNA transcript levels by regulating epigenetic marks. As such, we measured the association of repressive (H3K9met3 and H3K27met3) and active (H3K4met3 and H3K36met3) chromatin marks at the BDNF genomic locus (Fig. 6a) .
After depleting BDNF-AS by siRNA, we performed chromatin immunoprecipitation (ChIP) assays. We designed 16 primers to span the entire 270-kb region extending through to the neighboring 
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A r t i c l e s genes LIN7C and KIF18A. We studied the immunoprecipitated DNA using individual primer sets using rtPCR and we found that the siRNA-mediated depletion of the BDNF-AS transcript caused reduction in H3K27me3 association in both the sense-antisense overlapping region, indicated by primer set 9, and in the upstream BDNF promoter region (Fig. 6b) . We found similar reduction in H3K27me3 binding to the promoter of the mouse Bdnf gene upon treatment of N2a cells with mBdnf-antagoNAT9 (Supplementary Fig. 15 ). Furthermore, we found that alterations in repressive marks were specific to H3K27me3, as we were not able to detect notable changes in H3K9me3, H3K4me3 and H3K36me3 (Supplementary Fig. 16) . These data suggest that BDNF-AS might play a role in the guidance, introduction and maintenance of H3K27me3 at the BDNF locus. EZH2 is a histone lysine methyltransferase largely responsible for the addition of the repressive mark, H3K27me3 (ref. 43) . We observed that the ablation of EZH2 activity using two different siRNAs produced the same phenotype as the BDNF-AS knockdown and caused upregulation of BDNF mRNA (Fig. 6c) . After treating cells with BDNF-AS siRNA, we used ChIP to track changes in EZH2 binding to the BDNF locus and observed a reduction in EZH2 binding at the BDNF promoter ( Fig. 6d) . However, not all 16 primer sets gave detectable PCR signals, which could be attributed to the lack of direct binding of EZH2 to chromatin. Given the reduced presence of EZH2 and the loss of the H3K27me3 at the BDNF promoter when BDNF-AS is knocked down, we conclude that BDNF-AS inhibits BDNF mRNA transcription by recruiting EZH2 and likely other members of the polycomb repressive complex 2 (PRC2) to the BDNF promoter region. Removal or inhibition of BDNF-AS could lead to the locus-specific upregulation of BDNF mRNA and protein.
DISCUSSION
NATs, likely for a host of different genes, can be manipulated to obtain locus-specific alteration in chromatin modification and therefore gene expression. How might low copy number NATs exert such a wide range of effects? It is becoming apparent that antisense RNA molecules exert local effects by maintaining or modifying chromatin structure, ultimately activating or suppressing sense gene expression 9, 44 . As examples, we show here that cleavage or inhibition of the antisense transcripts of BDNF, GDNF and EPHB2 genes leads to the upregulation of corresponding mRNAs. In the context of the work presented here, antagoNATs could be used as a therapeutic strategy to inhibit BDNF-AS and consequently enhance neuronal proliferation and survival in a variety of disease states. Upregulating the endogenous BDNF gene, with this strategy, may result in the production of RNA molecules that contain all natural modifications and represent relevant spliced isoforms. Further studies will be required to evaluate the merits of this approach versus administering synthetic BDNF molecules, for example.
We propose that EZH2, and likely the entire PRC2 complex, is necessary for the action of BDNF-AS and other similar NATs. Along with EZH2, at least three other proteins (EED, SUZ12 and RBAP48) are known to make up the core components of PRC2. Recent studies provide evidence for direct RNA-protein interaction between EZH2 and many noncoding RNA transcripts 45 . Studies of X-chromosome inactivation 46 and the HOX gene cluster 47 show that RNA transcripts are involved in the PRC2-mediated induction of H3K27me3 repressive chromatin marks. Over 9,000 RNA molecules, many of them antisense RNA transcripts interact with PRC2 in embryonic stem cells 45 . Epigenetic silencing of p15 and DM1 are reported to involve heterochromatin formation by its antisense RNA 48, 49 . How the NAT and EZH2/PRC2 components interact remains to be investigated; however, targeting NAT-EZH2 interaction might have therapeutic implications, especially for neurodegenerative disorders, where the upregulation of BDNF is desirable.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/. 
ONLINE METHODS
Mouse studies. We obtained approval for mouse studies from the Institutional Animal Care and Use Committee at The Scripps Research Institute, where the animal experiments were performed. We used 10 eight-week-old male C57BL/6 mice for in vivo experiments. We prepared mice with chronic indwelling cannulae in the dorsal third ventricle implanted subcutaneously with osmotic mini-pumps that delivered continuous infusions (0.11 µl/h) of synthetic antisense oligonucleotide directed against Bdnf-AS (mBdnf-antagoNAT9) or control oligonucleotide (inert sequence (CCACGCGCAGTACATG) that does not exist in human or mouse at a dose of 1.5 mg/kg/d for 4 weeks. We connected tubing to the exit port of the osmotic mini-pump and tunneled it subcutaneously to the indwelling cannula, such that the treatments were delivered directly into the brain. At 5 d after implantation all animals received daily intraperitoneal injection of BrdU (80 mg/kg) for five consecutive days. At 28 d after surgery, we euthanized the animals and excised three tissues (hippocampus, frontal cortex and hypothalamus) from each mouse brain for quantitative RNA measurements.
Design of modified antagoNAT molecules. We designed and tested a number of DNA-based antisense oligonucleotides, termed antagoNATs, targeting noncoding Bdnf-AS and other antisense transcripts. We designed various antagoNATs ranging from 12 to 20 nucleotides in length with or without full phosphorothioate modification plus/minus 2′-O-methyl RNA or LNA-modified nucleotides. We observed the highest efficacy on Bdnf mRNA levels with 16-nucleotide phosphorothioate gapmer with three LNA-modified nucleotides 40 at each end (XXXnnnnnnnnnnXXX). For blocking interactions between human BDNF sense-antisense transcripts, we used 14-nucleotide oligonucleotide containing both LNA and 2′-O-methyl RNA molecules. Although these 2′-O-methyl RNA-modified oligonucleotides are suggested to only block the RNA, we observed marginal downregulation of targeted RNAs in this experiment (Supplementary Fig. 12 ). Sequences of various antagoNATs, as well as all other siRNAs, primers and probes used for these studies are listed in Supplementary Table 1. RACE. Sequence information for the potential mouse Bdnf-AS was retrieved from the UCSC Genome Bioinformatics web site. Using RACE-ready cDNA (Ambion) from the mouse brain we amplified the 5′ and 3′ ends of Bdnf-AS by nested PCR with gene specific and kit primers. Alternatively, using 250 ng poly(A) RNA from the testis as starting materials and utilizing the PRLM RACE kit (Applied Biosystems), we generated 5′ and 3′ end libraries and performed PCR followed by sequencing to identify the mouse Bdnf-AS transcript. We excised the 3′ and 5′ PCR products of both mouse and human from an agarose gel and cloned them into the T-Easy vector (Promega). We sequenced positive colonies from each series.
rtPCR. We carried out rtPCR with the GeneAmp 7900 machine (Applied Biosystems). cDNA synthesis reaction contained random hexamers, 200-400 ng of RNA, 2.5 mM mixture of dNTP, MgCl 2 and appropriate buffer. The PCR reactions contained 20-40 ng cDNA, Universal Mastermix, 300 nM of forward and reverse primers, and 200 nM of probe in a final reaction volume of 15 µl. We designed the primer/probe set using FileBuilder software (Applied Biosystems). Primers were strand specific for sense-antisense pairs and the probes covered exon boundaries to eliminate the chance of genomic DNA amplification. The PCR conditions for all genes were as follows: 50 °C for 2 min then 95 °C for 10 min then 40 cycles of 95 °C for 15 s and 60 °C for 1 min (50 cycles for mouse Bdnf-AS). The results are based on cycle threshold (Ct) values. We calculated the differences between the Ct values for experimental and reference genes (18S RNA) as ∆∆Ct and graphed them as a percent of each RNA to the calibrator sample. We assessed the relative expression of BDNF and BDNF-AS RNA transcripts in several human and mouse cell lines by rtPCR. We measured the expression of Bdnf and Bdnf-AS transcripts in several mouse brain regions and other mouse tissues, including: testis, ovary, liver, spleen, thymus, lung, kidney, heart, embryo and cerebellum in wild-type C57BL/6 mice (n = 3) by rtPCR.
We measured the expression of both transcripts in a commercially available panel of human tissue RNA samples (Ambion), including: total brain, cervix, ovary, spleen, kidney, testis, esophagus, thyroid, adipose, skeletal muscle, bladder, colon, small intestine, liver, lung, prostate, heart, trachea, thymus and whole embryo. We measured expression of both transcripts in a panel of commercially available, 12-week-old embryonic RNA samples (Ambion), including: embryonic brain, liver, lung, heart, kidney, muscle and whole embryo.
We measured expression of Bdnf and Bdnf-AS in a panel of monkey brain RNA samples (n = 2) by rtPCR using human primers and probe. The brain regions tested from the monkey samples were: (i) motor cortex, (ii) frontal cortex, (iii) hippocampus, (iv) amygdala, (v) motor cortex, (vi) insula, (vii) temporal cortex, (viii) interior partial cortex, (ix) striatum, (x) cerebellum, (xi) striatum, (xii) septum, (xiii) occipital cortex and (xiv) pituitary gland. Both BDNF and BDNF-AS transcripts were expressed in many tissues and cell lines tested, and the expression of BDNF mRNA was 10-to 100-fold greater than the BDNF-AS transcript.
RNA extraction and rtPCR of the mouse brain samples. We euthanized mice after 28 d and excised the brains. One hemibrain from each mouse was fixed in 4% formaldehyde overnight for histological studies. We excised another hemibrain for RNA quantitative measurement from the hippocampus, frontal cortex and hypothalamus. We extracted RNA after homogenization in Trizol reagent (Invitrogen) according to the manufacturer's protocol. We separated the aqueous phase and added an equal volume of 70% ethanol before passing the samples through Qiagen RNeasy columns (QIAGEN) and we subjected those RNA samples to on-column DNAse treatment for removal of DNA contamination. We used 400 ng of each sample for the first-strand cDNA synthesis and carried out rtPCR measurements as described above. We plotted the percentile changes in RNA levels, for individual tissues as compared to control mice, in each graph.
Cell culture and transfection. We purchased human cortical neurons, HCN-1A, originating from the brain of an 18-month-old female (ATCC). These cells were reported to be positive for a number of neuronal markers including neurofilament protein, neuron specific enolase and gamma aminobutyric acid. We cultured cells in a DMEM medium supplemented with 10% FBS. We purchased human glial cells (ATCC) that originated from the brain of a 33-year-old male with malignant glioblastoma. We cultured these cells in a mixture of DMEM and F12 plus 10% FBS, 1% NEAA, 2.5 mM L-glutamate, 15 mM HEPES, 0.5 mM sodium pyruvate and 1% sodium bicarbonate. We cultured HEK293T, N2a, human cortical neuron (HCN1) and human glioblastoma MK059 cells in appropriate medium, and transfected cells in logarithmic growth, with 5-20 nM of siRNA or antisense oligonucleotides using 0.2% lipofectamine 2000 (Invitrogen), according to manufacturer's instructions. Antisense oligonucleotides are single-stranded, 14-nucleotide DNA strands with 2′-O-methyl and LNA modifications, complementary to the BDNF-AS sequence. We designed 14 functional and two inert control oligonucleotides (that do not have targets in the mammalian genome). Cells were incubated for various time points before RNA extraction, using Qiagen RNeasy columns.
Stability and a-amanitin treatment. We plated HEK293T cells into 6-well plates. We treated cells 24 h later with 50 mg/ml of α-amanitin and harvested cells for RNA purification and rtPCR at 6, 12 and 24 h after treatment. We collected three independent samples for each data point and all experiments included untreated matching samples for RNA purification and data analysis.
Statistical analysis.
We did all experiments with 6-20 biological and 3-6 technical repeats. The data presented in the graphs are a comparison with control-treated groups after post-hoc analysis of the corresponding treatment factor using main effects in a two-way analysis of variance (ANOVA). We calculated the significance of each treatment as a P-value. As depicted in each graph, (P < 0.05) was considered significant.
Western blot analysis. We transfected HEK293T cells with 10 nM of BDNF-AS, or control siRNA. We disrupted cells, 48 h after transfection, with 200 µl of Laemmli sample buffer (Bio-Rad) containing 350 mM DTT. We separated 20 µl of the lysate on a 10% SDS PAGE and transferred it to a nitrocellulose membrane overnight. Then we incubated the membrane with primary antibody for MecP2 (Abcam), BDNF (Promega) and secondary antibody conjugated to horseradish peroxidase. After addition of HRP substrate, we detected the npg
